275.00p+0.00 (+0.00 %)01 Dec 2020, 14:46
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Faron Pharmaceuticals Oy Fundamentals

Company NameFaron Pharmaceuticals OyLast Updated2020-12-01
Shares in Issue46.815 mMarket Cap£128.74 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-€0.31EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.1933Debt Equity Ratio0.3543
Asset Equity Ratio1.9613Cash Equity Ratio1.5899
Quick Ratio2.9813Current Ratio2.98
Price To Book Value0ROCE0

Faron Pharmaceuticals Oy Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Faron Pharmaceuticals Oy Company Financials

Tangible Assets€399,000.00€17,000.00€22,000.00
Intangible Assets€529,000.00€525,000.00€325,000.00
Total Fixed Assets€1.00 m€1.18 m€1.66 m
Debtors€955,000.00€596,000.00€1.92 m
Cash & Equivalents€7.06 m€4.07 m€9.31 m
Other Assets000
Total Assets€10.21 m€8.00 m€14.89 m
Creditors within 1 year€6.08 m€5.75 m€8.06 m
Creditors after 1 year€2.52 m€1.89 m€2.09 m
Other Liabilities000
Total Liabilities€8.60 m€7.63 m€10.14 m
Net assets€1.61 m€369,000.00€4.74 m
Called up share capital€2.69 m€2.69 m€2.69 m
Share Premium000
Profit / Loss-€13.25 m-€20.08 m-€21.06 m
Other Equity€1.61 m€369,000.00€4.74 m
Preference & Minorities000
Total Capital Employed€1.61 m€369,000.00€4.74 m
Debt Ratio€0.61€0.84€0.31
Assets / Equity1.96131.96131.9613
Cash / Equity1.58991.58991.5899
Cash Flow201920182017
Cash from operating activities-€11.52 m-€20.52 m-€18.36 m
Cashflow before financing€3.08 m-€4.98 m-€1.78 m
Increase in Cash€2.98 m-€5.28 m-€1.88 m
Cost of sales000
Gross Profit000
Operating Profit-€13.10 m-€19.99 m-€20.66 m
Pre-Tax profit-€13.25 m-€20.08 m-€21.06 m

Faron Pharmaceuticals Oy Company Background

ActivitiesFaron Pharmaceuticals Oy is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is a anti-viral and anti-inflammatory agent, being tested in several Phase III studies around the world against COVID-19.
Latest Interim Date24 Sep 2020
Latest Fiscal Year End Date20 Mar 2020

Faron Pharmaceuticals Oy Directors

2020-10-14Dr. Gregory B. Brown,M.D.Director
2020-10-14Dr. Frank Murdoch ArmstrongChairman
2018-09-13Dr. Huaizheng PengDirector
2018-09-13Dr. Jonathan Kenneth Charles KnowlesDirector
2020-10-14Mr. Matti Esa MannerVice Chairman
2020-10-14Mr. Leopoldo Giampaolo ZambelettiDirector
2020-10-14Dr. Markku Tapani JalkanenChief Executive Officer
2019-05-31Mr. Yrjo Erik Kristian WichmannChief Financial Officer
2019-11-08Mr. Juho Markku JalkanenDirector
2020-10-14Mr. John PoulosDirector
2020-10-14Mr. Toni HanninenChief Financial Officer

Faron Pharmaceuticals Oy Contact Details

Company NameFaron Pharmaceuticals Oy
AddressJoukahaisenkatu 6, Intelligate, Turku, FI-20520
Telephone+358 24695151

Faron Pharmaceuticals Oy Advisors

Financial PR AdviserConsilium Strategic Communications
Phone+44 2037095700
Financial PR AdviserWestwicke Partners
Phone+1 339 970-2843
StockbrokerPanmure Gordon (UK) Ltd
Phone+44 2078862500
SolicitorJones Day
Phone+44 2070395959
Fax+44 2070395999
Phone+358 9 22 800
Fax+358 9 174 102
SolicitorHannes Snellman
Nominated AdviserCairn Financial Advisers LLP
Phone+44 2072130880
StockbrokerWhitman Howard
Phone+44 2076591234